Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Recent publications published by researchers at the MRC WIMM.

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Aksöz M. et al, (2024), Sci Immunol, 9

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Freeman SD. et al, (2023), Blood, 142, 1697 - 1707

A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), STAR Protoc, 4

A hematopoietic stem cell subset that retains memory of prior inflammatory stress accumulates in aging and clonal hematopoiesis

Zeng AGX. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Load More